The Structural Genomics Consortium at the Goethe University Frankfurt (SGC Frankfurt) is focused on the development of selective inhibitors (chemical probes), which help us to better understand the biological role of key signaling molecules and may serve as a starting point to target these proteins in different diseases. The SGC Frankfurt is committed to sharing its research in the spirit of Open Science.
SGC Frankfurt will be hosting the SGC science day 2019 at Goethe University, Riedberg campus, on Thursday, June 6, starting 8:50 am. If you are interested in quality control, chemical tools and application in human disease you are welcome to join the event. For further information please click here.
LRRK2 is a major target for Parkinson's disease therapies. Determination of a high-resolution crystal structure of the full-length LRRK2 protein or individual functional domains protein would help understanding the molecular basis of this disease and, importantly, provide a structural basis for rational drug design. Read more
Stolz A, Dikic I. Elusive mitochondrial connection to inflammation uncovered. Nature. 2018 Link
Drewes G, Knapp S. Chemoproteomics and Chemical Probes for Target Discovery. Trends Biotechnol. 2018 Link
Georgi V, Schiele F, Berger BT, Steffen A, Marin Zapata PA, Briem H, Menz S, Preusse C, Vasta JD, Robers MB, Brands M, Knapp S, Fernández-Montalván A. Binding Kinetics Survey of the Drugged Kinome. J Am Chem Soc. 2018 Link
Chief Operating Officer
Tel: +49 (0) 69 798-42501
contact (at) sgc-frankfurt.de
60438 Frankfurt am Main